428 related articles for article (PubMed ID: 22307805)
1. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Stummer W; Meinel T; Ewelt C; Martus P; Jakobs O; Felsberg J; Reifenberger G
J Neurooncol; 2012 May; 108(1):89-97. PubMed ID: 22307805
[TBL] [Abstract][Full Text] [Related]
2. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
[TBL] [Abstract][Full Text] [Related]
3. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
4. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
[TBL] [Abstract][Full Text] [Related]
5. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
6. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
8. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
[TBL] [Abstract][Full Text] [Related]
10. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
11. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
12. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
Capdevila L; Cros S; Ramirez JL; Sanz C; Carrato C; Romeo M; Etxaniz O; Hostalot C; Massuet A; Cuadra JL; Villà S; Balañà C
J Neurooncol; 2014 Mar; 117(1):77-84. PubMed ID: 24395350
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
15. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of molecular biomarkers in glioblastoma.
Ang C; Guiot MC; Ramanakumar AV; Roberge D; Kavan P
Can J Neurol Sci; 2010 Sep; 37(5):625-30. PubMed ID: 21059509
[TBL] [Abstract][Full Text] [Related]
17. The Impact of
Jovanović N; Mitrović T; Cvetković VJ; Tošić S; Vitorović J; Stamenković S; Nikolov V; Kostić A; Vidović N; Krstić M; Jevtović-Stoimenov T; Pavlović D
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30717206
[No Abstract] [Full Text] [Related]
18. Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution.
Céfaro GA; Genovesi D; Vinciguerra A; Trignani M; Taraborrelli M; Augurio A; Buonaguidi R; Galzio RJ; Di Nicola M
Strahlenther Onkol; 2011 Dec; 187(12):778-83. PubMed ID: 22127356
[TBL] [Abstract][Full Text] [Related]
19. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
